How Should Brands Plan a Personal Lubricant 510(k) Submission?

A U.S. personal lubricant launch is not only a formula and packaging project. It connects the intended use, exact formulation, performance specifications, labeling, manufacturing controls, FDA listing, and post-market responsibilities.

For B2B buyers, the first decision is which regulatory route the brand will follow:

• Private label an existing FDA 510(k)-cleared formula without changing it.
• Modify or develop a formula and complete the appropriate new regulatory route.
• Build a proprietary formula program under the brand’s own submission strategy.

This decision affects cost, timing, claims, testing, supplier agreements, and who carries each compliance responsibility.

◆ Featured Answer: What Is a Personal Lubricant 510(k) Submission?

A personal lubricant 510(k) submission is a premarket notification used to demonstrate substantial equivalence to a legally marketed predicate device. FDA classifies personal lubricants under product code NUC and 21 CFR 884.5300 as Class II devices generally subject to 510(k) requirements.

A 510(k) is a clearance, not a product certification and not the same as premarket approval. A successful route normally requires a defined intended use, an appropriate predicate, a controlled formulation, supporting performance and biological-safety evidence, compliant labeling, and consistent manufacturing controls.

Brands can review FDA’s personal lubricant device classification and 510(k) premarket notification overview.

◆ Which Regulatory Route Should a Brand Choose?

◇ Route 1: Use an Existing 510(k)-Cleared Formula

This is usually the more direct U.S. market route when a brand accepts an already cleared formula without modification.

Kenier Co currently coordinates four FDA 510(k)-cleared formula routes through its lubricant manufacturing partner:

• Three water-based formulas.
• One silicone-based formula.

The K-numbers are not displayed publicly. They can be provided during qualified project due diligence with the relevant clearance and formula documents.

The brand must use the exact cleared formulation and remain within the supported intended use and labeling scope. The 510(k) holder must provide written authorization, and the brand’s proprietary or trade name must be added to the applicable FDA device listing.

Before artwork approval, the buyer should confirm:

• Legal 510(k) holder and manufacturer.
• Cleared device name and intended use.
• Exact formula covered by the clearance.
• Written private-label authorization.
• Proprietary-name listing process.
• Final label identity and address.
• Complaint, traceability, recall, and importer responsibilities.

FDA explains that current private-label names should be included in device listings. It also states that a distributor generally does not file a separate 510(k) merely because the manufacturer’s unchanged device is sold under the distributor’s company name.

Brands comparing supply routes can review this guide to China lubricant suppliers with FDA 510(k)-related formula support.

◇ Route 2: Modify a Formula

Fragrance, flavor, color, viscosity, thickener systems, and other characteristics can be changed technically. However, the modified product should not automatically be marketed under the original clearance.

Under Kenier Co’s current private-label route, the existing clearance applies only to the exact cleared formula. Changing fragrance, flavor, color, viscosity, an ingredient, or an ingredient proportion moves the project out of that route. The modified formula requires a documented regulatory assessment and the appropriate new FDA clearance before it is represented as 510(k)-cleared.

Changes may affect:

• pH and osmolality.
• Viscosity and flow behavior.
• Ingredient exposure and toxicological profile.
• Preservative effectiveness and microbial control.
• Stability and shelf life.
• Condom compatibility, when claimed.
• Packaging compatibility.
• Label directions and warnings.
• Biological-safety evidence.

FDA’s guidance on changes to an existing device should be reviewed with a qualified U.S. regulatory professional.

◇ Route 3: Develop a Proprietary Formula

A proprietary formula can provide stronger differentiation, but it creates a larger technical and regulatory scope.

The brand should define the intended use, formula type, sensory target, ingredient restrictions, packaging, claims, shelf-life target, responsible U.S. parties, predicate strategy, testing plan, and submission budget before development starts.

For brands still selecting a formula direction, this comparison of water-based and silicone-based lubricant sourcing explains how formula type affects compatibility, positioning, and documentation.

◆ What Do the Current Cleared Formula Directions Contain?

Kenier Co can disclose ingredient names but not confidential proportions.

One current water-based formula direction includes:

• Purified water.
• Propylene glycol.
• Hydroxyethyl cellulose.
• Potassium sorbate.
• Citric acid.
• EDTA-2Na.
• Sodium polyacrylate.
• Sodium hyaluronate.

The current silicone-based formula direction includes:

• Dimethicone.
• Dimethiconol.

The ingredient lists above correspond to one current water-based formulation and one current silicone-based formulation that have already received FDA 510(k) clearance. The exact ingredient proportions form part of the proprietary formulation specifications and are not disclosed publicly. Each marketed product must remain consistent with the formulation, manufacturing controls, labeling, and supporting evidence covered by its clearance.

◆ How Should Brands Select a Predicate?

Predicate selection should begin with intended use, not with a formula that merely looks similar.

A useful comparison covers:

• Intended use and user population.
• Anatomical contact and contact duration.
• Water-based or silicone-based technology.
• Formulation characteristics.
• pH, osmolality, viscosity, and other specifications.
• Condom or material-compatibility claims.
• Packaging and delivery system.
• Directions, warnings, and limitations.

The submission should identify an appropriate primary predicate and explain why differences do not raise new questions of safety and effectiveness. This decision should be made before expensive testing begins.

◆ What Testing and Documentation May Be Needed?

There is no universal one-page checklist for every lubricant. The evidence plan depends on the formula, intended use, contact type, claims, predicate, process, and packaging.

◇ Formula and Performance Controls

• Master formula and ingredient specifications.
• Finished-product specifications.
• pH, osmolality, viscosity, and appearance limits.
• Fill-volume controls.
• Batch release criteria.
• Certificate of Analysis format.

◇ Microbiological, Stability, and Packaging Evidence

• Microbial limits.
• Preservative-effectiveness testing when applicable.
• Accelerated and real-time stability.
• Shelf-life rationale and storage conditions.
• Bottle, pump, tube, sachet, foil-seal, leak, and container-closure checks.

◇ Biological-Safety Evidence

FDA recognizes ISO 10993-1 as a risk-management framework for body-contacting devices. The assessment should consider the finished formulation, nature and duration of mucosal contact, chemical characterization, toxicological information, and applicable biological endpoints.

It is not simply a fixed set of three tests. The team should document why the selected evidence is sufficient for the exact device. Brands can review FDA’s ISO 10993-1 guidance and coordinate suitable work with experienced adult product testing agencies.

Additional evidence may be needed for condom compatibility, flavored or warming formulas, special duration claims, or compatibility with specified device materials.

◆ How Does Private-Label FDA Listing Work?

When a brand sells the unchanged cleared device under its own trade name, the holder and manufacturing establishment document the relationship and add the proprietary name to the applicable FDA device listing.

This does not create a new 510(k). It records the trade name under which the already cleared device is marketed.

A practical sequence is:

1. Confirm the exact cleared formula.
2. Review the clearance, intended use, and formula documents.
3. Sign authorization and private-label agreements.
4. Freeze the formula, claims, fill size, and labeling.
5. Add the trade name to the applicable device listing.
6. Approve final packaging.
7. Complete samples and applicable checks.
8. Release production under controlled specifications.

FDA’s registration and listing FAQ explains the proprietary-name requirement. Registration and listing should never be described as FDA approval.

◆ What Should Appear on the Label?

A brand that is not the actual manufacturer should not identify itself simply as the manufacturer.

Depending on the documented relationship, the label may state:

• Manufactured for: [Brand Company Name]
• Distributed by: [Brand Company Name]

The applicable company name and place-of-business information should appear on the label. The parties may also identify both manufacturer and distributor when they choose to disclose the relationship.

FDA’s general device-labeling requirements explain these identity statements.

The final label should also match the cleared intended use, directions, warnings, ingredient presentation, storage information, lot traceability, expiration dating, and importer or distributor requirements.

◆ Who Is Responsible for the Project?

◇ Brand or Distributor

The brand defines the market, trade name, packaging, claims, and launch plan. Its agreement should cover complaint forwarding, traceability, product changes, artwork approval, importer responsibilities, and recall communication.

◇ 510(k) Holder and Manufacturer

The holder and manufacturer control the cleared formula, manufacturing process, specifications, quality records, authorization, device listing, change control, batch consistency, complaint evaluation, and applicable reporting.

◇ Production and Packaging Partners

The production team follows the approved formula, controls raw materials, documents batching, completes release testing, and verifies the final container-closure system.

◇ Regulatory Consultant

A qualified consultant can support classification, predicate research, change assessment, evidence strategy, labeling, and eSTAR preparation. Most 510(k)s must be submitted electronically through eSTAR.

Since February 2, 2026, FDA’s Quality Management System Regulation incorporates ISO 13485:2016 by reference. ISO 13485 certification and FDA product clearance remain separate concepts. See FDA’s QMSR overview.

◆ What Packaging and Commercial Options Are Available?

Kenier Co supports lubricant-specific packaging such as:

• 5 ml and 10 ml foil sachets.
• 50 ml, 60 ml, 100 ml, 120 ml, and 240 ml formats.
• Bottles, pump heads, soft tubes, and foil seals.
• Private-label artwork and outer packaging.

For the current 240 ml route:

• MOQ can start from 3,000 pieces.
• Samples usually take approximately 7–10 days.
• Bulk production usually takes approximately 25–30 days after confirmation.

Actual timing depends on formula, packaging availability, artwork, FDA listing work, testing, and order details. The current production route also uses an effective mixing batch of approximately 500 kg.

Brands should align projected volume, fill size, packaging MOQ, and regulatory route before beginning custom development. This guide can help buyers choose a lubricant for a sex toy brand.

◆ Pre-Launch Checklist for B2B Buyers

Before mass production, confirm:

• Applicable clearance record and written authorization.
• Exact controlled formula.
• Intended use and final claims.
• Proprietary-name listing status.
• Final label and packaging files.
• Ingredient list, SDS, and COA format.
• Finished-product specifications.
• Stability, microbiological, and biological-safety support.
• Claim-specific compatibility evidence.
• Approved container-closure specifications.
• Batch coding and traceability.
• Complaint, importer, recall, and reporting responsibilities.
• Signed change-control requirements.

No formula, flavor, color, fragrance, viscosity, claim, or packaging-contact change should be introduced informally after approval.

◆ People Also Ask

◇ Can a brand sell under a manufacturer’s existing lubricant 510(k)?

Yes, when the brand distributes the manufacturer’s unchanged cleared device under its own trade name. The project should use the exact formula, have written authorization, add the trade name to the applicable listing, and use accurate wording such as “Manufactured for” or “Distributed by.”

◇ Can a brand change the viscosity, fragrance, flavor, or color?

These characteristics can be developed, but the modified product should not be represented under the original clearance without the appropriate regulatory work. Kenier Co treats these changes as a new formulation route.

◇ Is adding a brand name to an FDA listing the same as obtaining clearance?

No. It records a trade name for the cleared device. It does not create a new clearance or represent FDA approval.

◇ When should a brand consider its own submission?

A brand should evaluate its own submission when it wants a proprietary formula, meaningful formulation changes, different intended use, new claims, greater regulatory control, or a supply strategy independent of the existing holder.

◆ Final Thoughts

A personal lubricant 510(k) submission should be planned before formula development and packaging approval.

Brands seeking the most direct U.S. private-label route can evaluate an exact cleared formula, written authorization, proprietary-name listing, and controlled labeling. Brands seeking a custom formula should plan for a new assessment, evidence package, and submission strategy.

The strongest project is one in which the formula, intended use, claims, packaging, quality controls, and commercial responsibilities all describe the same product.

Brands can review Kenier Co’s private label personal lube manufacturing options or contact Kenier Co with a lubricant project brief.